Back to Article

Drug-Receptor Interaction of Peptidic HIV-1 Protease: Intermolecular Interaction-III

Online Journal of Microbiological Research | Vol 3, Issue 1

Table 8. Calculation of ΔELH, ΔN and ΔE of EI-complexesformed, when HIV-1-PRIs interact with binding site on HIV-1-PR

No.DεHOMODεLUMOValIleNo.DεHOMODεLUMOValIle


RεHOMO =-10.09RεHOMO =-10.22RεHOMO =-10.09RεHOMO =-10.22
RεLUMO =0.67RεLUMO =0.46RεLUMO =0.67RεLUMO =0.46


ΔELHΔELHΔELHΔELH
1-9.711-0.22010.3789.99627-9.743-1.20710.4099.008
2-9.769-0.25010.4369.96528-9.764-0.17210.43110.043
3-9.563-1.14810.2299.06729-9.335-0.13910.0019.791
4-9.783-0.24010.4499.97530-9.706-0.14010.37210.075
5-9.779-0.17210.44610.04431-9.247-0.6189.9139.597
6-9.804-0.23310.4709.98332-9.720-0.60210.3879.613
7-9.817-0.29910.4839.91633-9.692-0.50110.3599.714
8-9.533-1.14610.2009.06934-9.427-0.96010.0949.255
9-9.628-0.24810.2949.96835-9.603-0.15510.26910.061
10-9.525-1.12610.1919.08936-9.766-0.15010.43210.065
11-9.646-0.20710.31310.00837-9.7850.00110.45110.216
12-9.515-1.22110.1818.99438-9.680-0.10410.34610.111
13-9.852-0.21810.5189.99739-9.7110.01410.37710.168
14-9.535-1.13210.2019.08340-9.787-0.00610.45410.209
15-9.699-0.23710.3659.97941-9.775-0.20910.44210.007
16-9.664-0.57110.3319.64442-9.759-0.12310.42510.092
17-9.433-1.22010.0998.99543-9.7640.02010.43010.221
18-9.690-0.15010.35710.06544-9.742-0.15010.40810.065
19-9.682-0.12210.34810.09445-9.500-0.16710.1669.957
20-9.724-0.13510.39110.08146-9.489-0.14610.1559.945
21-9.838-0.19510.50410.02047-9.780-0.00610.44710.209
22-9.682-0.64810.3489.56748-9.597-0.00910.26310.054
23-9.274-0.4929.9419.72349-9.754-0.04210.42010.174
24-9.784-1.01910.4509.196503.8554.990-3.18915.205
25-9.526-0.14510.1929.98351-9.784-0.16010.45110.056
26-8.911-0.1439.9489.368     

εHOMO: energy of highest occupied molecular orbital, εLUMO: energy of lowest unoccupied molecular orbital, ΔELH = εLUMO – εHOMO, χ: electronegativity, η: hardness, Val: valine, Ile: isoleucine, ΔN: shift in charge, ΔE: lowering of energy, and. R: receptor amino acid, D stand for drug (HIV-1-PRIs)